The MRC group reported that a > 3 log reduction in RUNX1-RUNX1T1 transcripts in the bone marrow in t(8;21)AML at end of induction, predicted for better RFS; the cumulative incidence of relapse (CIR) was 4% among the 47% of patients who achieved this MRD level versus 32% among those who did not. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.